ETRETINATE IN TREATMENT OF ACTINIC KERATOSIS. A Double-blind Crossover Study

The Lancet

Volumn 319, Issue 8268, 1982, Pages 364-365

  Moriarty, M ^a   Dunn, J ^a   Darragh, A ^b   Lambe, R ^b   Brick, I ^b  

^a ST LUKE S HOSPITAL   (Ireland)

^b Institute of Clinical Pharmacology ^*  (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETINATE; PLACEBO; RETINOL;

ACTINIC KERATOSIS; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; THERAPY;

AGED; CLINICAL TRIALS; DOUBLE-BLIND METHOD; ETRETINATE; FEMALE; HUMANS; KERATOSIS; MALE; MIDDLE AGED; RANDOM ALLOCATION; TRETINOIN;

EID: 0020078096     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(82)91393-9     Document Type: Article

References (11)

1. The biological function of vitamin A acid
2. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogues (retinoids)
3. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells
4. Oral vitamin A acid therapy
5. The cutaneous safety of topical tretionom
6. Systemic treatment of psoriasis with a new aromatic retinoid
7. Serum lipid changes during aromatic retinoid (Ro 10-9359) therapy for psoriasis
8. The influence of 'Tigason' (Ro 10-9359) on the serum lipoproteins in man
9. Tissue changes in psoriatic plaques after oral administration of retinoid
10. Oral retinoid treatment of human papillomavirus type 5 induced epidermodysplasia verruciformis